How to Get Trulicity (Dulaglutide) in Oklahoma

Trulicity (dulaglutide, made by Eli Lilly) is a GLP-1 receptor agonist given by injection once per week using a pre-filled pen. The FDA has approved it for two purposes in adults with type 2 diabetes: to lower blood sugar and to reduce the risk of heart attack, stroke, and other major cardiovascular events in those with existing heart disease or multiple cardiovascular risk factors. We focus here on these approved uses; we do not address compounded versions or use of dulaglutide specifically for weight loss, which involves separate evidence and regulatory questions.

In Oklahoma, the practical bottleneck for most patients is not finding someone licensed to write the prescription. Physicians, nurse practitioners, and physician assistants across the state can prescribe Trulicity, and telehealth prescribing is legal without a prior in-person visit. The harder problems are insurance-specific: Oklahoma's Medicaid program (SoonerCare) has not historically listed Trulicity as a preferred diabetes drug, and commercial plans generally require prior authorization and step therapy through metformin first. Those coverage rules change over time and by plan, so they need to be confirmed directly rather than assumed from a general guide.

Who can prescribe Trulicity in Oklahoma

Any Oklahoma-licensed prescriber with active prescriptive authority, including MDs, DOs, nurse practitioners, and physician assistants, can prescribe dulaglutide. Oklahoma allows nurse practitioners to obtain independent practice authority after meeting the state's supervised-practice requirements, and PAs prescribe under a supervisory agreement with a physician. The exact hour requirements and scope-of-practice rules for NPs and PAs are set by Oklahoma statute and licensing board rule, and can change, so a prescriber's specific authority should be confirmed with the Oklahoma Board of Medical Licensure or the relevant licensing board rather than assumed.

Primary care providers write a large share of GLP-1 receptor agonist prescriptions nationally, not just endocrinologists, which matters in a state where endocrinology access is limited outside the Oklahoma City and Tulsa metro areas. If a current primary care provider is unfamiliar with GLP-1 therapy or hesitant to prescribe it, a telehealth visit with a provider who specializes in diabetes or obesity medicine is a reasonable alternative, provided the platform is licensed to prescribe in Oklahoma.

How telehealth prescribing works in Oklahoma

Oklahoma permits synchronous (live video) telehealth visits for prescribing non-controlled medications like Trulicity without requiring a prior in-person visit. Federal rules under the Ryan Haight Act govern controlled substance telehealth prescribing specifically; dulaglutide is not a controlled substance, so those specific restrictions do not apply to it, though general telehealth practice standards still do.

A typical pathway looks like this:

1. Complete an intake covering diabetes history, current A1c, weight, comorbidities, and current medications.
2. A licensed provider reviews the intake and conducts a live video visit to assess whether dulaglutide is clinically appropriate, including screening for contraindications.
3. If appropriate, the provider sends an electronic prescription to a pharmacy of your choice.

Visit availability and how quickly a prescription reaches the pharmacy vary by platform. If prior authorization is required by your insurer, that step adds time independent of how fast the visit itself happens.

Labs and screening before starting Trulicity

Prescribers commonly order baseline labs before starting a GLP-1 receptor agonist, consistent with general diabetes management practice: hemoglobin A1c, fasting glucose, a basic metabolic panel (including kidney function), and a lipid panel. Thyroid function tests, liver enzymes, and pancreatic enzymes are sometimes ordered as well, though practice varies by prescriber.

The FDA requires a boxed warning for dulaglutide because thyroid C-cell tumors developed in rodent studies; human relevance at prescribed doses remains unknown. Dulaglutide is contraindicated in anyone with medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 syndrome in their personal or family history, and prescribers should confirm this absence before dispensing. In parallel, researchers are investigating GLP-1 receptor activity in different cancer types for prognostic clues; this emerging area of tumor biology is distinct from the animal thyroid finding and does not alter dulaglutide's current approved uses or contraindications (Wang et al., 2025, https://pubmed.ncbi.nlm.nih.gov/39777709/). Early mechanistic cancer research should not be read as proof of clinical harm.

Labs from a recent visit, generally within the prior few months, are often accepted by telehealth providers if uploaded during intake, which can avoid duplicate testing.

Does Oklahoma Medicaid (SoonerCare) cover Trulicity?

Trulicity has not been a preferred agent on Oklahoma's Medicaid preferred drug list for type 2 diabetes. This is a real access barrier for SoonerCare enrollees who might otherwise be good candidates for the drug. Preferred drug lists are reviewed and updated periodically by the Oklahoma Health Care Authority, so this status can change and should be verified directly against the current OHCA preferred drug list or by calling SoonerCare member services before assuming coverage either way.

Providers can submit a prior authorization exception request for a non-preferred drug, but approval is not guaranteed and depends on documented clinical justification. Patients who lose SoonerCare eligibility during a redetermination cycle and move to a marketplace or employer plan may gain different formulary access, again subject to that plan's own rules.

Commercial insurance and prior authorization

Most commercial insurers operating in Oklahoma cover Trulicity but require prior authorization, and formulary tier placement (and the resulting copay) varies by insurer and plan year. A prior authorization request typically needs to document a confirmed type 2 diabetes diagnosis, a current A1c value, and a trial of (or documented intolerance or contraindication to) metformin, along with a clinical rationale for choosing dulaglutide. Turnaround times, appeal processes, and exact documentation requirements are set by each payer and change over time, so they should be confirmed with the specific plan rather than assumed from a general figure.

Dulaglutide's cardiovascular outcomes trial (REWIND) reported a reduction in major adverse cardiovascular events in a broad type 2 diabetes population that included many patients without established cardiovascular disease at baseline. The exact effect size and confidence interval should be verified against the primary REWIND publication before being cited in an appeal letter or clinical note, since secondary summaries (including earlier versions of this page) have sometimes misstated trial numbers. More broadly, GLP-1 receptor agonists as a drug class have been studied for cardiac effects beyond glycemic control, and that class-level evidence can provide useful background context (Ussher & Drucker, 2016, https://pubmed.ncbi.nlm.nih.gov/27531946/), but class-level findings should not be assumed to apply identically to every individual GLP-1 drug or dose.

Manufacturer savings programs

Eli Lilly has historically offered a savings card for commercially insured patients and a separate patient assistance program (Lilly Cares) for uninsured or low-income patients who do not qualify for the savings card. Terms such as monthly cost caps, program duration, and income eligibility thresholds change periodically and are not valid for patients using government insurance such as Medicare, Medicaid, Tricare, or VA benefits. Confirm current terms directly on the manufacturer's program page or by calling the number listed on the Trulicity pen packaging before assuming a specific dollar figure applies.

Pharmacy options in Oklahoma

Retail chain pharmacies. Major chains across Oklahoma metro areas generally stock or can order Trulicity. It is a refrigerated product, so proper cold-chain handling during transit and storage matters if you use mail order.

Specialty pharmacies. Some insurers require Trulicity to be filled through a designated specialty pharmacy rather than a retail location, particularly on high-deductible or specialty-tier plans.

503A compounding pharmacies. Oklahoma-licensed 503A pharmacies may compound preparations under individual prescriptions, but FDA guidance limits when compounding a copy of an FDA-approved commercially available drug is appropriate, generally reserving broader compounding flexibility for periods of documented drug shortage (per FDA compounding guidance). Compounded dulaglutide is not an FDA-approved finished product, has not been reviewed by the FDA for safety, efficacy, or manufacturing quality in the same way as the branded pen, and its use should be discussed explicitly with the prescriber, including whether dulaglutide is currently listed on an FDA shortage list at all. If it is not, compounding a copy of it raises the same legal and quality concerns that apply to compounding any non-shortage brand-name drug.

Transferring a Trulicity prescription to Oklahoma

Dulaglutide is not a controlled substance, so transferring an active prescription to an Oklahoma pharmacy is generally straightforward. Contact the new Oklahoma pharmacy with the current pharmacy's name, phone number, and prescription number, and the receiving pharmacist can initiate the transfer. If no refills remain, a new prescription from an Oklahoma-licensed provider is required; telehealth visits can often issue this if you provide recent labs and diabetes management records for continuity of care.

Dosing overview (not individualized guidance)

The FDA label describes dulaglutide dosing as a titration: starting at a low weekly dose for a minimum period, then increasing in steps if additional glycemic control is needed, up to a maximum weekly dose, with a minimum interval required between dose increases. The specific starting dose, titration pace, and target dose for any individual patient should be determined by the prescribing clinician based on that patient's glycemic goals, tolerability, and other medical conditions, not from a general guide. Gastrointestinal side effects such as nausea, vomiting, and diarrhea are dose-dependent and most common during titration, and typically improve over several weeks at a stable dose, though this varies by patient.

What is established, what is plausible, and what is not established

Established: Dulaglutide is FDA-approved for type 2 diabetes and for cardiovascular risk reduction in a specific type 2 diabetes population with cardiovascular disease or multiple risk factors. It carries a boxed warning for thyroid C-cell tumors based on rodent data and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Telehealth prescribing of non-controlled medications like dulaglutide is legal in Oklahoma without a prior in-person visit.

Plausible but requiring verification for a given patient or plan: Specific prior authorization criteria, formulary tier, copay amount, manufacturer savings card terms, and cash price at a given Oklahoma pharmacy on a given date. These change frequently and are not governed by a single fixed federal rule.

Not established from the evidence available here: Oklahoma-specific counts of endocrinologists or lab draw sites, exact statewide diabetes prevalence rankings, and any claim that early research on tumor GLP-1 receptor expression changes dulaglutide's clinical risk profile. Precise numbers of this kind should be sourced directly from the relevant state or federal database before being repeated as fact.

Verification checklist: stable facts vs. facts you must confirm before your visit

Stable, unlikely to change without a formal FDA or federal action (safe to rely on as general background):

• Dulaglutide's FDA-approved indications (type 2 diabetes; cardiovascular risk reduction in a defined population)
• The boxed warning for thyroid C-cell tumors and the MTC/MEN 2 contraindication
• That dulaglutide is not a federally controlled substance
• That Ryan Haight Act restrictions govern controlled substance telehealth prescribing, not dulaglutide specifically
• The general concept that compounding a copy of an FDA-approved drug is legally constrained outside documented shortage conditions

Date-sensitive, confirm before or at your visit (do not assume from any general article, including this one):

• Whether Trulicity is currently preferred or non-preferred on the Oklahoma SoonerCare drug list, and current exception-request procedures, confirm with OHCA or your MCO
• Your specific commercial plan's formulary tier, copay, and prior authorization documentation requirements, confirm with your insurer or pharmacy benefits manager
• Current Trulicity savings card terms, eligibility, and monthly cap, and current Lilly Cares income thresholds, confirm on the manufacturer's program materials
• Current cash price at your chosen Oklahoma pharmacy
• Whether dulaglutide currently appears on an FDA drug shortage list (relevant if a 503A pharmacy proposes a compounded version)
• Current Oklahoma NP/PA scope-of-practice rules if you are relying on a non-physician prescriber for an independent visit

When to seek urgent care instead of waiting on this process: signs of a severe allergic reaction, severe abdominal pain that could indicate pancreatitis, or symptoms of a thyroid mass such as a new neck lump, hoarseness, or difficulty swallowing warrant prompt medical evaluation rather than waiting for a routine telehealth or pharmacy timeline.

Frequently asked questions

References

• Wang et al. Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types. 2025. https://pubmed.ncbi.nlm.nih.gov/39777709/
• Ussher JR, Drucker DJ. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. 2016. https://pubmed.ncbi.nlm.nih.gov/27531946/

This article is for general education and does not replace individualized medical advice. Coverage, pricing, and program terms referenced above change over time and must be confirmed directly with the relevant payer, pharmacy, or manufacturer program before you rely on them. This draft is pending qualified clinical and editorial review.